Next Article in Journal
Introduction
Previous Article in Journal
Conflict of Interest in Health Technology Assessment Decisions: Case Law in France and Impact on Reimbursement Decisions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 3
Issue 1
10.3402/jmahp.v3.27902
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Perspective

Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France

by
Mondher Toumi
1,*,
Cécile Rémuzat
2,
Emna El Hammi
3,
Aurélie Millier
2,
Samuel Aballéa
2,
Christos Chouaid
4,5 and
Bruno Falissard
6
1
Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, France
2
Creativ-Ceutical, Paris, France
3
Evidenz, Tunis, Tunisia
4
INSERM U955 and Université Paris Est (UPEC), UMR U955, Faculté de Médecine, F-94010 Créteil, France
5
Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, F-94000 Créteil, France
6
INSERM Unit U669 (Public Health and Mental Health), University Paris-Sud, Maison de Solenn, Paris, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2015, 3(1), 27902; https://doi.org/10.3402/jmahp.v3.27902
Submission received: 18 March 2015 / Revised: 9 April 2015 / Accepted: 15 April 2015 / Published: 4 June 2015

Abstract

The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommendations and health economic opinions. This article provides an in-depth description of the CEESP's structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France. It also points out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment in France. The authors also provide their personal opinion on the likely future of health economic assessment of drugs in France, including the possible merge of the CEESP and the Transparency Committee, the implementation of a French threshold, and the extension of health economic assessment to a larger number of products.
Keywords: health economic assessment; CEESP; HAS; France; market access; cost-effectiveness health economic assessment; CEESP; HAS; France; market access; cost-effectiveness

Share and Cite

MDPI and ACS Style

Toumi, M.; Rémuzat, C.; El Hammi, E.; Millier, A.; Aballéa, S.; Chouaid, C.; Falissard, B. Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France. J. Mark. Access Health Policy 2015, 3, 27902. https://doi.org/10.3402/jmahp.v3.27902

AMA Style

Toumi M, Rémuzat C, El Hammi E, Millier A, Aballéa S, Chouaid C, Falissard B. Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France. Journal of Market Access & Health Policy. 2015; 3(1):27902. https://doi.org/10.3402/jmahp.v3.27902

Chicago/Turabian Style

Toumi, Mondher, Cécile Rémuzat, Emna El Hammi, Aurélie Millier, Samuel Aballéa, Christos Chouaid, and Bruno Falissard. 2015. "Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France" Journal of Market Access & Health Policy 3, no. 1: 27902. https://doi.org/10.3402/jmahp.v3.27902

APA Style

Toumi, M., Rémuzat, C., El Hammi, E., Millier, A., Aballéa, S., Chouaid, C., & Falissard, B. (2015). Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France. Journal of Market Access & Health Policy, 3(1), 27902. https://doi.org/10.3402/jmahp.v3.27902

Article Metrics

Back to TopTop